ACP-105
Legal status
Legal status
Identifiers
  • 2-chloro-4-(3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbenzonitrile
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC16H19ClN2O
Molar mass290.79 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1Cl)C#N)N2C3CCC2CC(C3)(C)O
  • InChI=1S/C16H19ClN2O/c1-10-14(6-3-11(9-18)15(10)17)19-12-4-5-13(19)8-16(2,20)7-12/h3,6,12-13,20H,4-5,7-8H2,1-2H3
  • Key:OUEODVPKPRQETQ-UHFFFAOYSA-N

ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline.[1][2][3][4] The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor β agonist AC-186.[3] ACP-105 is an aniline SARM and is related to AC-262536 and vosilasarm (RAD140).[5]

References

  1. ↑ Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, et al. (November 2009). "Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators". Journal of Medicinal Chemistry. 52 (22): 7186–7191. doi:10.1021/jm901149c. PMID 19856921.
  2. ↑ Dayger C, Villasana L, Pfankuch T, Davis M, Raber J (March 2011). "Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice". Brain Research. 1381: 134–140. doi:10.1016/j.brainres.2010.12.088. PMC 3048897. PMID 21219889.
  3. 1 2 George S, Petit GH, Gouras GK, Brundin P, Olsson R (December 2013). "Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease". ACS Chemical Neuroscience. 4 (12): 1537–1548. doi:10.1021/cn400133s. PMC 3867967. PMID 24020966.
  4. ↑ Cutler C, Viljanto M, Taylor P, Hincks P, Biddle S, Van Eenoo P (October 2021). "Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes". Drug Testing and Analysis. 14 (2): 349–370. doi:10.1002/dta.3189. hdl:1854/LU-8740373. PMID 34714606. S2CID 240152623.
  5. ↑ Zhang X, Sui Z (February 2013). "Deciphering the selective androgen receptor modulators paradigm". Expert Opinion on Drug Discovery. 8 (2): 191–218. doi:10.1517/17460441.2013.741582. PMID 23231475. S2CID 2584722.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.